• 1
    Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210;474485.
  • 2
    West WH, Tauer KW, Yannelli JR et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316;898905.
  • 3
    Phillips JM, Gemlo BT, Myers WW, Rayner AA, Lanier LL. In viro and in vitro activation of natural killer cells in advanced cancer patients undergoing combiticd recombinant interleukin-2 and LAK cell therapy. J Clin Oncol 1987; 5:193341.
  • 4
    McMannis JD, Eisher RI, Creekmore SP, Braun DP, Harris JE, Ellis TM. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. J Immunol 1988; 140:133540.
  • 5
    Weil-Hillman G, Voss SD, Fisch P et al. Natural killer cells activated by interleukin-2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the Tac negative phenotype Cancer Res 1990; 50;268391.
  • 6
    Weidmann E, Bergmann L, Hechler P, Mitrou PS. Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer patients with interleukin-2. Cancer Immunol Immunother 1991; 33:398402.
  • 7
    Mitchell MS, Kempf RA, Harel W et al. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 1988; 6;40924.
  • 8
    Hermann GG, Geertsen PF, Von der Maase H, Zeuthen J. Interleukin-2 dose, blood monocyteand CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma. Cancer Immunol Immunother 1991; 34:11114.
  • 9
    Sondel PM, Kohler PC, Hank JA et al. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988; 48;25617.
  • 10
    Foa R, Guarini A, Tos AG et al. Peripheral blood and bone marrow immunophenotypic and functional modifications indueed in acute leukemia palienls treated with interleukin 2: evidence ofin vivo lymphokine activated killer cell generation. Cancer Res 1991; 51;9648.
  • 11
    Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77:25618.
  • 12
    Thompson JA, Lee DJ, Lindgren CG et al. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res 1989; 49;23540.
  • 13
    Lotze MT, Matory YL, Ettinghausen SE et al. In vivo administration of purified human inlerleukin-2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid eells in vivo with recombinant IL-2 J Immunol 1985; 135;286575.
  • 14
    Gambacorti-Passerini C, Radrizzani M, Marolda R et al. In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2 Int J Cancer 1988; 41;7006.
  • 15
    Thompson JA, Lee DJ, Lindgren CG et al. Influence of dose and duration of interleukin-2 on toxieiiy and immunomodulation. J Clin Oncol 1988; 6;66978.
  • 16
    Fortis C, Eerrero E, Besana C et al. recombinant interleukin- 2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells. Cancer Imtiiunol Immunother 1990; 32;1616.
  • 17
    Skettino S, Phillips J, Lanier L, Nagler A, Greenberg P. Selective generation of erythroid hurst-promoting activity by recombinant interleukin 2-stimulated human T lymphocytes and natural killer cells. Blood 1988; 71:90714.
  • 18
    Sehaafsma MR, Falkenhurg JHF, Landegent JE et al. In vivo production of interleukin-5, granulocyte-macrophagecolony-stimulating factor, macrophage colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients Blood 1991; 78;15817.
  • 19
    Waldmann TA. The multi-subunit interleukin-2 receptor. Annu Rev Biochem 1989; 58:875911.
  • 20
    Arima N, Kamio M, Imada K et al. Pseudo-high affinity interleukin 2 (IL-2) receptor lacks the third componeni that is essential for functional IL-2 binding and signaling. J Exp Med 1992; 176;126572.
  • 21
    Ohashi Y, Takeshita T, Nagata K, Mori S, Sugamura K. Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral hlood mononuclear ceils. J Immunol 1989; 143:354855.
  • 22
    Ortaldo JR, Winckler-Pickett RT, Yagita H, Young HA. Comparative studies of CD3- and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol 1991; 136:48695.
  • 23
    Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989; 143:318391.
  • 24
    Akbar AN, Terry L, Timms A, Beverley PCL, Janossy G. Loss of CD45R and gain of UCHL1 isa feature of primed Tcells. J Immunol 1988; 140:21718.
  • 25
    Braakman E, Sturm E, Vijverberg K, van Krimpen BA, Gratama JW, Bolhuis RLH. Expression of CD45 isoforms by fresh and activated human gamma-delta T lymphocytes and natural killer cells. Int Immutiol 1991; 3:6917.
  • 26
    Punt CJA, Janscn RLH, de Mulder PHM et al. Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study. J Immunother 1992; 12;27784.
  • 27
    Loken MR, Brosnan JM, Bach BA, AuK KA. Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry. Cytometry 1990; 11:4539.
  • 28
    van Putten WLJ, Kortboyer J, Bolhuis RLH, Gratama JW, Three-marker phenotypic analysis of lymphocytes based on two-color immunofluorescence using a multinomial model for How cytometric counts and maximum likelihood estimation. Cytomelry 1993; 14;17987.
  • 29
    Konrad MW, Hemstreet G, Hersh EM et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res 1990; 50;200917.
  • 30
    Voss SD, Robb RJ, Weil-Hillman G et al. Increased expression of the interleukin 2 (IL-2) receptor β chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding. J Exp Med 1990; 172;110114.
  • 31
    Caliguri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subsel with high alRnity receptors. J Exp Med 1990; 171;150926.
  • 32
    Nagler A, Lanier LL, Phillips JH. Constitutive expression of high affinity interleukin 2 receptors on human CD16- natural killer cells in vivo. J Exp Med 1990; 171:152733.
  • 33
    La Salle JM, Hafler DA. The coexpression of CD45RA and CD45RO isoforms on T cells during the S/G2/M stages of cell cycle. Cell rmmunol 1991; 138:197206.
  • 34
    Warren HS, Skipsey LJ. Loss of activation-induced CD45RO with maintenance of CD45RA expression during prolonged culture of T cells and NK cells. Immunology 1991; 74:7885.